Skip to content
Screener

ARS Pharmaceuticals, Inc. SPRY Cash & Equivalents

Cash & Equivalents at other companies

Aquestive Therapeutics, Inc. logo
Aquestive Therapeutics, Inc.AQST
$110.73M+61.3%
Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
$127.64M+78.4%
Viatris logo
ViatrisVTRS
$890M+56.7%
AMP
Amphastar PharmaceuticalsAMPH
$223.61M+19.1%
Neuropace, Inc. logo
Neuropace, Inc.NPCE
$15.63M-42.4%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$19.66M+12.9%

Other financials

Income statement

See full
Revenue$22.7M+184%
Operating income-$60.1M-61.8%
Net income-$60.6M-78.6%
EPS (diluted)-$0.61-74.3%

Balance sheet

See full
Total debt$96.5M+132,122%
Total equity$61.3M-73.2%
Total assets$287.6M-12.1%

Cash flow

See full
Operating cash flow-$44.9M-10.3%
CapEx--100%
Free cash flow-$44.9M-10.1%

Valuation

See full
Market cap$611.71M-62.0%
Enterprise value$683.91M-56.1%
P/S6.2×-8.1×

Profitability

See full
Operating margin-204.5%—
Net margin-200%-219pp
FCF margin-177.1%-206pp

Returns & leverage

See full
Return on equity-136.4%-144pp
Debt / equity1.6×+1.6×
Current ratio4.9×-6.1×

Where this comes from

Reported directly by ARS Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The source filing: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026.

Filed
May 15, 2026, 6:17 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-225142
Line itemMarch 31, 2026December 31, 2025
(unaudited)
Assets
Current assets:
Cash and cash equivalents$24,321$41,317
Short-term investments176,648203,669
Accounts receivable, net28,66225,347
Inventories8,8178,369
Prepaid expenses and other current assets6,7886,194

Item 1. Financial Statements

FAQ

What is ARS Pharmaceuticals, Inc.'s cash & equivalents?
ARS Pharmaceuticals, Inc. (SPRY) reported cash & equivalents of $24.32M in Q1 2026.
How has ARS Pharmaceuticals, Inc.'s cash & equivalents changed year-over-year?
ARS Pharmaceuticals, Inc.'s cash & equivalents decreased by 39.0% year-over-year, from $39.86M to $24.32M.
What is the long-term trend for ARS Pharmaceuticals, Inc.'s cash & equivalents?
Over 5 years (2020 to 2025), ARS Pharmaceuticals, Inc.'s cash & equivalents has grown at a -36.1% compound annual growth rate (CAGR), from $386.92M to $41.32M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Ask your AI about ARS Pharmaceuticals, Inc.'s cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude